Immunosuppressants Market Size, Share, Trends, Growth and Forecast Report 2021-2027

Description

The global Immunosuppressants market garnered revenue around USD 15,998.1 million in 2020 and projected to reach USD 44,712.40 million in 2027, with at a compound annual growth rate (CAGR) 15.9% throughout the estimate period from 2021 to 2027. Immunosuppressants belong to the drug family that helps in suppressing the immune response or agents. During organ transplantation, from a donor to a recipient, immune system of the recipient gets stimulated and thus, produces immune response like it does in response to other foreign material. This immune response causes serious damage to the transplanted or grafted organ. It is often called as rejection, which can be acute or chronic. This organ rejection is prohibited by using immunosuppressive drugs, which block the immune response and protect new organ and its function. They are mainly used to avert several autoimmune diseases including myasthenia gravis, arthritis, lupus, rheumatoid arthritis, Crohn’s disease, and organ transplant rejections such as transplant of kidney, liver, and heart. There are three stages of clinical immunosuppression: induction therapy, maintenance therapy, and treatment of an established acute rejection response. 

This research report encompasses precise assessment of the market with the help of comprehensive qualitative insights and supportable prognoses regarding market size, consumption and production. The projections presented in the report have been derived using proven research methodologies and assumptions. It does so by means of comprehensive qualitative insights, historical statistics, and verifiable predictions about market revenue and sales.

The rapidly budding threat owed to the eruption of COVID-19 is impacting lives, communities, businesses, and industries across the globe. With businesses shuttered, flights grounded, COVID-19 is about to affect the global economy in different ways such as by directly upsetting production and demand, by generating supply chain disruption, and by its financial impact on firms and financial markets. Therefore, this report covers COVID-19 outbreak impact analysis on the Immunosuppressants market under the research study. The market estimates offered in the report are the outcome of in-depth extensive secondary research, primary interviews and in-house professional assessments. These market evaluations have been measured by reviewing the impact of numerous social, political and economic factors coupled with recent market dynamics affecting the Immunosuppressants market growth.

The global Immunosuppressants market is characterized by the presence of numerous small as well as medium scale companies. These players are largely focused towards forward integration via raw material production, product manufacturing, and distribution across various industry verticals. The report recognizes numerous crucial manufacturers of the market. This research study aids to comprehend the strategies and associations that companies are converging to survive in this competitive marketplace. This report assists in understanding footprints of the manufacturers with the help of their global revenue, production, capacity and average selling price analysis for period 2016-2027.

Major manufacturers analysed under this study comprises:

Comprehensive competitive analysis and profiles of major immunosuppressant market players such as Astellas Pharma, Inc., Bristol Myers Squibb, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc., Intas Pharmaceuticals Ltd., Johnson & Johnson, Mylan Laboratories Inc., Novartis AG, Pfizer, Inc., and Sanofi S.A are provided in this report.

This report delivers market breakdown and its revenue, consumption, production analysis and projections by categorizing it depending on parameters such as type, application/end-user, and region. This research report delivers the analysis and prognosis of revenue, production, price, market share and growth trend for different products such as:

By Drug Class

·         Corticosteroids

·         Monoclonal Antibodies (mAbs)

·         Calcineurin Inhibitors

·         mTOR Inhibitors

·         Anti-Proliferative Agents

·         Others

By Indication

·         Organ Transplantation

·         Autoimmune Disorders

·         Non-Autoimmune Inflammatory Diseases

By Distribution Channel

·         Hospital pharmacies

·         Retail pharmacies

·         Online pharmacies

Regional Analysis and Forecast

Further, this research study analyses market size, production, consumption and its advancement trends at global, regional, and country level for period 2016 to 2027 and covers following region in its scope: 

 

North America

United States

Canada

 

Europe

Germany

United Kingdom

Italy

France

Rest of EU

 

Asia Pacific

China

India

Japan

Southeast Asia

Rest of APAC

 

Central & South America 

Brazil 

Argentina

Rest of Central & South America 

 

Middle East and Africa

GCC

North Africa

South Africa

TABLE OF CONTENT

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Immunosuppressants Market, By Drug Class

7.1.  Immunosuppressants Market, by Drug Class, 2021-2027

7.1.1.    Corticosteroids

7.1.1.1.        Market Revenue and Forecast (2016-2027)

7.1.2.    Monoclonal Antibodies (mAbs)

7.1.2.1.        Market Revenue and Forecast (2016-2027)

7.1.3.    Calcineurin Inhibitors

7.1.3.1.        Market Revenue and Forecast (2016-2027)

7.1.4.    mTOR Inhibitors

7.1.4.1.        Market Revenue and Forecast (2016-2027)

7.1.5.    Anti-Proliferative Agents

7.1.5.1.        Market Revenue and Forecast (2016-2027)

7.1.6.    Others

7.1.6.1.        Market Revenue and Forecast (2016-2027)

Chapter 8.  Global Immunosuppressants Market, By Indication

8.1.  Immunosuppressants Market, by Indication, 2021-2027

8.1.1.    Organ Transplantation

8.1.1.1.        Market Revenue and Forecast (2016-2027)

8.1.2.    Autoimmune Disorders

8.1.2.1.        Market Revenue and Forecast (2016-2027)

8.1.3.    Non-Autoimmune Inflammatory Diseases

8.1.3.1.        Market Revenue and Forecast (2016-2027)

Chapter 9.  Global Immunosuppressants Market, By Distribution Channel

9.1.  Immunosuppressants Market, by Distribution Channel, 2021-2027

9.1.1.    Hospital pharmacies

9.1.1.1.        Market Revenue and Forecast (2016-2027)

9.1.2.    Retail pharmacies

9.1.2.1.        Market Revenue and Forecast (2016-2027)

9.1.3.    Online pharmacies

9.1.3.1.        Market Revenue and Forecast (2016-2027)

Chapter 10.      Global Immunosuppressants Market, Regional Estimates and Trend Forecast

10.1.        North America

10.1.1.  Market Revenue and Forecast, by Drug Class (2016-2027)

10.1.2.  Market Revenue and Forecast, by Indication (2016-2027)

10.1.3.  Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.1.4.  U.S.

10.1.4.1.      Market Revenue and Forecast, by Drug Class (2016-2027)

10.1.4.2.      Market Revenue and Forecast, by Indication (2016-2027)

10.1.4.3.      Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.1.5.  Rest of North America

10.1.5.1.      Market Revenue and Forecast, by Drug Class (2016-2027)

10.1.5.2.      Market Revenue and Forecast, by Indication (2016-2027)

10.1.5.3.      Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.2.        Europe

10.2.1.  Market Revenue and Forecast, by Drug Class (2016-2027)

10.2.2.  Market Revenue and Forecast, by Indication (2016-2027)

10.2.3.  Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.2.4.  UK

10.2.4.1.      Market Revenue and Forecast, by Drug Class (2016-2027)

10.2.4.2.      Market Revenue and Forecast, by Indication (2016-2027)

10.2.4.3.      Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.2.5.  Germany

10.2.5.1.      Market Revenue and Forecast, by Drug Class (2016-2027)

10.2.5.2.      Market Revenue and Forecast, by Indication (2016-2027)

10.2.5.3.      Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.2.6.  France

10.2.6.1.      Market Revenue and Forecast, by Drug Class (2016-2027)

10.2.6.2.      Market Revenue and Forecast, by Indication (2016-2027)

10.2.6.3.      Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.2.7.  Rest of Europe

10.2.7.1.      Market Revenue and Forecast, by Drug Class (2016-2027)

10.2.7.2.      Market Revenue and Forecast, by Indication (2016-2027)

10.2.7.3.      Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.3.        APAC

10.3.1.  Market Revenue and Forecast, by Drug Class (2016-2027)

10.3.2.  Market Revenue and Forecast, by Indication (2016-2027)

10.3.3.  Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.3.4.  India

10.3.4.1.      Market Revenue and Forecast, by Drug Class (2016-2027)

10.3.4.2.      Market Revenue and Forecast, by Indication (2016-2027)

10.3.4.3.      Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.3.5.  China

10.3.5.1.      Market Revenue and Forecast, by Drug Class (2016-2027)

10.3.5.2.      Market Revenue and Forecast, by Indication (2016-2027)

10.3.5.3.      Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.3.6.  Japan

10.3.6.1.      Market Revenue and Forecast, by Drug Class (2016-2027)

10.3.6.2.      Market Revenue and Forecast, by Indication (2016-2027)

10.3.6.3.      Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.3.7.  Rest of APAC

10.3.7.1.      Market Revenue and Forecast, by Drug Class (2016-2027)

10.3.7.2.      Market Revenue and Forecast, by Indication (2016-2027)

10.3.7.3.      Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.4.        MEA

10.4.1.  Market Revenue and Forecast, by Drug Class (2016-2027)

10.4.2.  Market Revenue and Forecast, by Indication (2016-2027)

10.4.3.  Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.4.4.  GCC

10.4.4.1.      Market Revenue and Forecast, by Drug Class (2016-2027)

10.4.4.2.      Market Revenue and Forecast, by Indication (2016-2027)

10.4.4.3.      Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.4.5.  North Africa

10.4.5.1.      Market Revenue and Forecast, by Drug Class (2016-2027)

10.4.5.2.      Market Revenue and Forecast, by Indication (2016-2027)

10.4.5.3.      Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.4.6.  South Africa

10.4.6.1.      Market Revenue and Forecast, by Drug Class (2016-2027)

10.4.6.2.      Market Revenue and Forecast, by Indication (2016-2027)

10.4.6.3.      Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.4.7.  Rest of MEA

10.4.7.1.      Market Revenue and Forecast, by Drug Class (2016-2027)

10.4.7.2.      Market Revenue and Forecast, by Indication (2016-2027)

10.4.7.3.      Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.5.        Latin America

10.5.1.  Market Revenue and Forecast, by Drug Class (2016-2027)

10.5.2.  Market Revenue and Forecast, by Indication (2016-2027)

10.5.3.  Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.5.4.  Brazil

10.5.4.1.      Market Revenue and Forecast, by Drug Class (2016-2027)

10.5.4.2.      Market Revenue and Forecast, by Indication (2016-2027)

10.5.4.3.      Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.5.5.  Rest of LATAM

10.5.5.1.      Market Revenue and Forecast, by Drug Class (2016-2027)

10.5.5.2.      Market Revenue and Forecast, by Indication (2016-2027)

10.5.5.3.      Market Revenue and Forecast, by Distribution Channel (2016-2027)

Chapter 11.  Company Profiles

11.1.              Astellas Pharma, Inc.

11.1.1.  Company Overview

11.1.2.  Product Offerings

11.1.3.  Financial Performance

11.1.4.  Recent Initiatives

11.2.              Bristol Myers Squibb

11.2.1.  Company Overview

11.2.2.  Product Offerings

11.2.3.  Financial Performance

11.2.4.  Recent Initiatives

11.3.              F. Hoffmann La Roche Ltd.

11.3.1.  Company Overview

11.3.2.  Product Offerings

11.3.3.  Financial Performance

11.3.4.  Recent Initiatives

11.4.              GlaxoSmithKline Plc.

11.4.1.  Company Overview

11.4.2.  Product Offerings

11.4.3.  Financial Performance

11.4.4.  Recent Initiatives

11.5.              Intas Pharmaceuticals Ltd.

11.5.1.  Company Overview

11.5.2.  Product Offerings

11.5.3.  Financial Performance

11.5.4.  Recent Initiatives

11.6.              Johnson & Johnson

11.6.1.  Company Overview

11.6.2.  Product Offerings

11.6.3.  Financial Performance

11.6.4.  Recent Initiatives

11.7.              Mylan Laboratories Inc.

11.7.1.  Company Overview

11.7.2.  Product Offerings

11.7.3.  Financial Performance

11.7.4.  Recent Initiatives

11.8.              Novartis AG

11.8.1.  Company Overview

11.8.2.  Product Offerings

11.8.3.  Financial Performance

11.8.4.  Recent Initiatives

11.9.              Pfizer, Inc.

11.9.1.  Company Overview

11.9.2.  Product Offerings

11.9.3.  Financial Performance

11.9.4.  Recent Initiatives

11.10.           Sanofi S.A

11.10.1.               Company Overview

11.10.2.               Product Offerings

11.10.3.               Financial Performance

11.10.4.               Recent Initiatives

Chapter 12.  Research Methodology

12.1.              Primary Research

12.2.              Secondary Research

12.3.              Assumptions

Chapter 13.  Appendix

13.1.              About Us

13.2.              Glossary of Terms

Choose License Type

Checkout Inquiry Sample